K K Jain MD (Dr. Jain is a consultant in neurology and has no relevant financial relationships to disclose.)
Originally released July 6, 1999; last updated April 8, 2016; expires April 8, 2019
Notice: Pemoline is no longer marketed in the United States because of the risk of liver toxicity. This article is retained for historical reasons. It is not available for CME credit.

Historical note and terminology

Pemoline is a central nervous system stimulant, but it is structurally dissimilar to amphetamines and methylphenidate. Pemoline was approved by the United States Food and Drug Administration in 1975. In 1999, pemoline was withdrawn in Canada due to liver complications. In 2005, the manufacturer withdrew pemoline in the United States after a consumer group petitioned the FDA about its safety.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology